Presentation to Jefferies Virtual Healthcare Conference
Telix Pharmaceuticals Limited has today announced that Group CBO Dr. David Cade presented at Jefferies Virtual Healthcare Conference
Telix Pharmaceuticals Appoints Dr Colin Hayward as Chief Medical Officer
Telix Pharmaceuticals announces that Dr Colin Hayward has joined Telix’s executive leadership team in the role of Chief Medical Officer (CMO).
Telix presents IPAX-1 study in glioblastoma treatment at ASCO 2020
Telix Pharmaceuticals is pleased to announce that the IPAX-1 study will be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program to be held May 29 – 31, 2020. IPAX-1 is a Phase 1/2 clinical study of TLX101 (also known as 131I-IPA or 4-L-[131I]iodo-phenylalanine) for patients with recurrent glioblastoma multiforme (GBM).
Telix Pharmaceuticals and Pharmalogic Enter US Distribution Agreement for Prostate Cancer Imaging
Telix Pharma (U.S.) announces it has entered into a commercial distribution agreement with Pharmalogic Holdings Corp
Telix Pharmaceuticals Granted July Pre-IND Meeting with US FDA for Phase III ProstACT Study
Telix has been granted a Type B pre-IND meeting with the FDA in relation to the Company’s planned Phase III ProstACT trial for TLX591
Telix AGM – Chairman and CEO Addresses
Telix is pleased to provide the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of Shareholders.
ARTMS and Telix Pharmaceuticals Announce Manufacturing Collaboration
ARTMS Products Inc. and Telix Pharmaceuticals Limited have entered into a development collaboration agreement
The Seneffe Manufacturing Site – Telix’s Next Big Move in Europe
Telix’s CEO Chris Behrenbruch comments on the Company’s next big move in Europe : the Seneffe manufacturing site.
Telix Submits European Marketing Authorisation Application for Prostate Cancer Imaging Product
Telix has submitted a marketing authorisation application (MAA) in Europe for TLX591-CDx
Seneffe Manufacturing Facility – Shareholder Walkthrough
Telix Pharmaceuticals Limited provides a shareholder walkthrough of it’s recently acquired Seneffe manufacturing facility